# Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure

> **NCT00293150** · PHASE4 · TERMINATED · sponsor: **The Cleveland Clinic** · enrollment: 11 (actual)

## Conditions studied

- Diastolic Heart Failure

## Interventions

- **DRUG:** Eplerenone

## Key facts

- **NCT ID:** NCT00293150
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-09
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Lack of eligible patients
- **Last updated:** 2017-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00293150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00293150, "Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00293150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*